Mid-dose rate intracavitary therapy for cervical cancer with a Selectron: a preliminary report.
Our early experience with Selectron MDR in treating cervical cancer patients at Osaka University Hospital is presented. From May 1991 through December 1992, a total of 22 patients (stage Ia, 1; stage Ib, 3; stage IIa, 1; stage IIb, 2; stage IIIb, 13 and stage IVa, 2) with previously untreated uterine cervical cancer and intact uterus were treated with mid-dose rate intracavitary therapy administered with a Selectron. A rigid applicator made of stainless steel for the Selectron was used for the treatment. The 137Cs source had an activity of 1.48 GBq as of reference time. Source loading corresponded to the Manchester System. Early tumor responses for all patients were complete. No acute radiation injury has been observed. There have been two local recurrences in stage IIIb patients. One of them developed para-aortic lymph node metastasis and died from distant metastasis. Another patient in stage IIIb had para-aortic and left supraclavicular lymph node metastasis and died from distant metastasis. Four patients developed rectal bleeding (grade 1, 3; grade 3, 1). One of them had been treated for aplastic anemia with steroid. The cause of grade 3 rectal bleeding was considered to be technical failure in intracavitary application. The remaining two patients recovered without treatment. From our early experience, it is concluded that Selectron MDR can be used for cervical cancer patients as safely and effectively as our previously used high-dose rate machine.
Teshima
T
T
Department of Radiology, Osaka University Medical School, Japan.
Inoue
T
T
Inoue
T
T
Ikeda
H
H
Yamazaki
H
H
Ohtani
M
M
Sasaki
S
S
Murayama
S
S
Kozuka
T
T
D001918:Brachytherapy / Q000009:adverse effects / Q000295:instrumentation*; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011879:Radiotherapy Dosage; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy*
D002588:Cesium Radioisotopes